Advertisement

PharmacoEconomics

, Volume 36, Issue 12, pp 1407–1420 | Cite as

Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?

  • Jorge Mestre-Ferrandiz
  • Néboa Zozaya
  • Bleric Alcalá
  • Álvaro Hidalgo-Vega
Current Opinion

Abstract

For medicines with different valued indications (uses), multi-indication pricing implies charging different prices for different uses. In this article, we assess how multi-indication pricing could help achieve overall strategic objectives of pricing controls, summarise its advantages and disadvantages (vs. uniform pricing) and estimate the hypothetical impact on prices of moving towards multi-indication pricing for specific oncologic medicines in Spain. International experience shows that multi-indication pricing can be implemented in real practice, and indeed a few initiatives are currently in use, albeit mostly applied indirectly through confidential pricing agreements that offer a way to discriminate prices across countries without altering list prices. However, some more sophisticated systems are in place in Italy, and more recently in Spain, where the objective is to monitor usage per patient/indication, and ultimately pay for outcomes. Based on the existing experience, we also outline six conditions required for multi-indication pricing. Multi-indication pricing is a useful tool to determine the relative prices of a drug for multiple (different-valued) indications, but by itself will not offer the ‘solution’ to what the absolute price should be. That will be driven, among other things, by cost-effectiveness thresholds, if they exist. Overall, we argue multi-indication pricing is nice in theory and it could work in practice, although changes in the manner in which medicines are priced, procured and monitored in clinical practice need to be applied.

Notes

Author Contributions

All authors made substantial contributions to this article. JM-F and AH-V conceived the idea and developed the theory. NZ and BA performed the analytic calculations. All authors discussed the results and contributed to the final manuscript.

Compliance with Ethical Standards

Funding

No funding was received for the preparation of this article.

Conflict of interest

Jorge Mestre-Ferrandiz, Néboa Zozaya, Bleric Alcalá and Álvaro Hidalgo-Vega have no conflicts of interest that are directly relevant to the contents of this article. Néboa Zozaya and Bleric Alcalá are employers of Weber, a consultancy firm that develops projects for pharmaceutical firms and other private and public clients.

References

  1. 1.
    Nayroles G, Frybourg S, Gabriel S, Kornfeld Å, Antoñanzas-Villar F, Espín J, et al. Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. J Mark Access Health Policy. 2017;5:1298190.CrossRefGoogle Scholar
  2. 2.
    Danzon P. Differential pricing of pharmaceuticals: theory, evidence and emerging issues. Pharmacoeconomics. 2018.  https://doi.org/10.1007/s40273-018-0696-4.CrossRefPubMedGoogle Scholar
  3. 3.
    Yadav P. Differential pricing for pharmaceuticals: review of current knowledge, new findings and ideas for action. London: Department for International Development; 2010.Google Scholar
  4. 4.
    Danzon P, Towse A, Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. Health Econ. 2015;24:294–301.CrossRefGoogle Scholar
  5. 5.
    Chandra A, Garthwaite C. The economics of indication-based drug pricing. N Engl J Med. 2017;377:103–6.CrossRefGoogle Scholar
  6. 6.
    Harvey J. Rewarding the factors of production: the marginal productivity theory of distribution. Economics revision guide. London: Palgrave; 1994.Google Scholar
  7. 7.
    European Commission. EXPH, 2018. Innovative payment for high-cost innovative medicines. A report of the Expert Panel on Effective Ways of Investing in Health (EXPH). Luxembourg: Publications Office of the European Union. European Commission; 2018. https://ec.europa.eu/health/expert_panel/sites/expertpanel/files/docsdir/opinion_innovative_medicines_en.pdf. Accessed 4 Sept 2018.
  8. 8.
    Finance and NHS/Medicines, Pharmacy and Industry Group/17080. The pharmaceutical price regulation scheme 2014, vol 2013. Department of Health, London, p. 135.Google Scholar
  9. 9.
    The Office of Fair Trading. The pharmaceutical price regulation scheme. An OFT market study. 2007. http://webarchive.nationalarchives.gov.uk/20140402181205/http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft885.pdf. Accessed 4 Sept 2018.
  10. 10.
    World Health Organization. How to develop and implement a national drug policy. 2nd ed. Geneva: World Health Organization; 2001.Google Scholar
  11. 11.
    OECD. Pharmaceutical pricing policies in a global market. OECD health policy studies. Paris: OECD Publishing; 2008. https://www.oecd-ilibrary.org/social-issues-migration-health/pharmaceutical-pricing-policies-in-a-global-market_9789264044159-en. Accessed 31 Jul 2018.
  12. 12.
    OECD. Achieving better value for money in health care. 2009. http://www.oecd-ilibrary.org/social-issues-migration-health/achieving-better-value-for-money-in-health-care_9789264074231-en. Accessed 31 Jul 2018.
  13. 13.
    European Commission. Pricing and reimbursement of medicinal products: growth. 2018. https://ec.europa.eu/growth/sectors/healthcare/competitiveness/products-pricing-reimbursement_en. Accessed 31 Jul 2018.
  14. 14.
    Themed section: US Value Assessment Frameworks. Value in Health, Feb 2018, vol 21, isuue 2, p. 117–165.Google Scholar
  15. 15.
    Zozaya N, Martínez L, Alcalá B, Hidalgo-Vega A. Informe evaluación, financiación y regulación de los medicamentos innovadores en los paises desarrollados. Weber; 2017. http://weber.org.es/publicacion/informe-evaluacion-financiacion-y-regulacion-de-los-medicamentos-innovadores-en-los-paises-desarrollados/. Accessed 5 Sept 2018.
  16. 16.
    Paris V, Belloni A. Value in pharmaceutical pricing. 2013. Report no. 63. http://www.oecd-ilibrary.org/social-issues-migration-health/value-in-pharmaceutical-pricing_5k43jc9v6knx-en. Accessed 5 Sept 2018.
  17. 17.
    Neuman P, Cohen J. Measuring the value of prescription drugs. N Engl J Med. 2015;373:2595–7.CrossRefGoogle Scholar
  18. 18.
    Towse A, Cole A, Zamora, B. The debate on indication based pricing in the U.S. and five major European countries. London: OEH Consulting; 2018.Google Scholar
  19. 19.
    Cole A, Towse A, Lorgelly P, Sullivan R. Economics of innovative payment models compared with single pricing of pharmaceuticals. OHE Res Pap 1804, Office of Health Economics, London, 2018.Google Scholar
  20. 20.
    Yeung K, Li M, Carlson JJ. Using performance-based risk-sharing arrangements to address uncertainty in indication-based pricing. J Manag Care Spec Pharm. 2017;23:1010–5.PubMedGoogle Scholar
  21. 21.
    Delgado O, Vilanova M, Díaz E, Blasco I, Llodrá V, Pinteño M. Proyecto talaoit: seguridad, calidad y seguimiento del paciente onco-hematológico en Baleares. Madrid: SEFH; 2016.Google Scholar
  22. 22.
    Doly A, Courdert B, Cottu P, Grandfils N, Pinguet J, Machuron V, et al. The personalised reimbursement models (PRM): real world data collection to provide innovative pricing solutions in France. Value Health. 2017;20:A743.CrossRefGoogle Scholar
  23. 23.
    Plaza F. Medición de resultados en salud: modelos personalizados de reembolso. Valencia: Congreso Nacional de la Sociedad Española de Farmacia Hospitalaria, SEFH; 2015.Google Scholar
  24. 24.
    Cole A, Mestre-Ferrandiz J, Towse A. Data governance arrangements for real-world evidence. Office of Health Economics; 2015. https://www.ohe.org/publications/data-governance-arrangements-real-world-evidence. Accessed 5 Sept 2018.
  25. 25.
    Hampson G, Towse A, Dreitlein B, Henshall C, Pearson SD. Real world evidence for coverage decisions: opportunities and challenges: a report from the 2017 ICER Membership Policy Summit. London: OHE; 2018: p. 39.Google Scholar
  26. 26.
    Shah S, Black J, Ramesh V, Shao D, Narayanan S. Conceptualization of an indication-specific pricing model to assess potential savings to a U.S. health plan. J Clin Oncol. 2017;35:e18315.CrossRefGoogle Scholar
  27. 27.
    Mestre-Ferrandiz J, Towse A, Dellamano R, Pistollato M. Multi-indication pricing: pros, cons and applicability to the UK. London: OHE; 2015.Google Scholar
  28. 28.
    Bernal-Delgado E, García-Armesto S, Oliva J, Martínez FIS, Repullo JR, Peña-Longobardo LM, et al. Spain: health system review 2018. Health Syst Transit. 2018;20(2):1–179.PubMedGoogle Scholar
  29. 29.
    Fundación Instituto Roche. Hacia un sistema sanitario basado en la creación de valor. 2015. https://www.institutoroche.es/jornadas/62-hacia-un-sistema-sanitario-basado-en-la-creacion-de-valor. Accessed 6 Mar 2018.
  30. 30.
    Bach PB. Indication-specific pricing for cancer drugs. JAMA. 2014;312:1629–30.CrossRefGoogle Scholar
  31. 31.
    Persson U, Norlin JM. Multi-indication and combination pricing and reimbursement of pharmaceuticals: opportunities for improved health care through faster uptake of new innovations. Appl Health Econ Health Policy. 2018;16(2):157–65.CrossRefGoogle Scholar
  32. 32.
    National Institute for Health and Care Excellence. Value based assessment of health technologies. 2009. https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/VBA-TA-Methods-Guide-for-Consultation.pdf. Accessed 5 Sept 2018.
  33. 33.
    Castañeda Macías I, Martínez-Brocal Ogayar I, Alegre del Rey EJ, Marín Gil R. Nivolumab en Cáncer de Pulmón no microcítico de células escamosas metastásico en segunda línea de tratamiento. Informe de evaluación para la Guía Farmacoterapéutica de Hospitales de Andalucía. 2016. Grupo GENESIS. Madrid: SEFH. Google Scholar
  34. 34.
    Gutierrez Lorenzo M, Morales Lara MJ, Espinosa Bosch, Fraga Fuentes MD, Alegre del Rey EJ, Asensi Díez R. NIVOLUMAB en carcinoma urotelial localmente avanzado irresecable o metatásico en adultos tras terapia previa basada en platino. 2017. Grupo GENESIS. Madrid: SEFH.Google Scholar
  35. 35.
    Fariñas Campos Q, Alegre-del Rey EJ. Nivolumab en cáncer de pulmón no microcítico no escamoso, en segunda línea de tratamiento. 2016. Grupo GENESIS. Madrid: SEFH.Google Scholar
  36. 36.
    Informe de Nivolumab en Carcinoma de Células Renales. 2016. Grupo GENESIS. Madrid: SEFH.Google Scholar
  37. 37.
    Consell Assessor de Medicació Hospitalària de Dispensació Ambulatòria (CAMHDA). Nivolumab. Tractament en monoteràpia de pacients adults amb melanoma avançat (irresecable o metastàtic). 2016. Barcelona. Departament de Salut. Barcelona: Generalitat de Catalunya.Google Scholar
  38. 38.
    Espinosa M, Bautista J, Santos B. Trastuzumab en cáncer gástrico metastásico. 2011. Grupo GENESIS. Madrid: SEFH.Google Scholar
  39. 39.
    Lozano Blázquez A, Fernández López de Vicuña EM, Carbajales Álvarez M. Trastuzumab. Informe para la Comisión de Farmacia y Terapéutica del Hospital Cabueñes. 2008. Grupo GENESIS. Madrid: SEFH.Google Scholar
  40. 40.
    Alegre del Rey EJ, Carmen Martínez Díaz C, Castaño Lara R, Sierra Sánchez J. Bevacizumab en cáncer colorrectal metastásico. Informe de evaluación para la Comisión de Farmacia y Terapéutica del Hospital Universitario de Puerto Real. 2009. Grupo GENESIS. Madrid: SEFH.Google Scholar
  41. 41.
    Cantudo Cuenca MR, Marín Gil R. Bevacizumab en cáncer de ovario. Informe para la Comisión de Farmacia y Terapéutica del Área de Gestión Sanitaria Sur de Sevilla. H.U. de Valme). 2015. Grupo GENESIS. Madrid: SEFH.Google Scholar
  42. 42.
    Alegre del Rey E, Martínez Díaz C, Fénix Caballero S. Bevacizumab en cáncer de pulmón no microcítico Informe para la Comisión de Farmacia del Hospital Universitario de Puerto Real. 2011. Grupo GENESIS. Madrid: SEFH.Google Scholar
  43. 43.
    Informe de Bevacizumab en cáncer de pulmón no microcítico. Informe para la Comisión de Farmàcia i Terapèutica de I’Institut Català d’Oncologia. 2009. Barcelona: Institut Català d’Oncologia.Google Scholar
  44. 44.
    Gándara Ladrón MJ, Espinosa Bosch M, Marín Gil R, Clopés Estela A, Alegre del Rey E, Arocas Casañ V, Asensi Diez R, Fraga Fuentes MD. Nab-Paclitaxel en primera línea de cáncer de páncreas metastásico. 2014. Grupo GENESIS. Madrid: SEFH.Google Scholar
  45. 45.
    Caracuel de Castro F, Mariscal Vázquez R, Muñoz Muñoz N, Ramírez Soto G, Gavira Moreno R. Paclitaxel-nab en Cáncer de Mama Metastásico. Informe para la Guía Farmacoterapéutica de Hospitales de Andalucía. 2010. Grupo GENESIS. Madrid: SEFH.Google Scholar
  46. 46.
    SEFH. Grupo de evaluación de novedades, estandarización e investigación en selección de medicamentos. https://gruposdetrabajo.sefh.es/genesis/. Accessed 29 Jun 2018.
  47. 47.
    Vallejo-Torres L, Garcia-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746–61.CrossRefGoogle Scholar
  48. 48.
    Vogler S, Haasis M, Dedet G, Lam J, Pedersen HB. Medicines reimbursement policies in Europe. Copenhagen: WHO Regional Office for Europe’s Health Technologies and Pharmaceuticals Programme; 2018.Google Scholar
  49. 49.
    Garattini L, Curto A. Performance-based agreements in Italy: “trendy outcomes” or mere illusions? Pharmacoeconomics. 2016;34:967–9.CrossRefGoogle Scholar
  50. 50.
    Pearson SD, Dreitlein B, Henshall C. Indication-specific pricing of pharmaceuticals in the United States health care system. Report from the ICER. 2015. http://icer-review.org/wp-content/uploads/2016/03/Final-Report-2015-ICER-Policy-Summit-on-Indication-specific-Pricing-March-2016_revised-icons.pdf. Accessed 27 Sept 2017.
  51. 51.
    Agenzia Italiana del Farmaco. Procedure applicazione managed entry agreements. 2017. http://www.aifa.gov.it/content/procedure-applicazione-managed-entry-agreements. Accessed 21 Nov 2017.
  52. 52.
    Palozzo AC. New drugs: how much are they worth? The Italian registries: a model to evaluate appropriateness and effectiveness. Eur J Hosp Pharm Sci Pract. 2012;19:398–403.CrossRefGoogle Scholar
  53. 53.
    Navarria A, Drago V, Gozzo L, Longo L, Mansueto S, Pignataro G, et al. Do the current performance-based schemes in Italy really work? “Success fee”: a novel measure for cost-containment of drug expenditure. Value Health. 2015;18:131–6.CrossRefGoogle Scholar
  54. 54.
    Messori A, De Rosa M, Pani L. Alternative pricing strategies for cancer drugs. JAMA. 2016;313:857.CrossRefGoogle Scholar
  55. 55.
    Pauwels K, Huys I, Vogler S, Casteels M, Simoens S. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol. 2017;4(8):171.  https://doi.org/10.3389/fphar.2017.00171.CrossRefGoogle Scholar
  56. 56.
    Flume M, Bardou M, Capri S, Sola-Morales O, Cunningham D, Levin L-A, et al. Feasibility and attractiveness of indication value-based pricing in key EU countries. J Mark Access Health Policy. 2016;10:4.  https://doi.org/10.3402/jmahp.v4.30970.CrossRefGoogle Scholar
  57. 57.
    NHS England Cancer Drugs Fund Team. Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry. 2016, London.Google Scholar
  58. 58.
    McNamara L, McNamara S. Testing the utility of the NHS’s systemic anti-cancer therapy data set for multi-indication pricing. Value Health. 2014;17:A659.CrossRefGoogle Scholar
  59. 59.
    Systemic Anti-Cancer Therapy. Chemotherapy dataset. http://www.chemodataset.nhs.uk/home. Accessed 14 Dec 2017.
  60. 60.
    Instituto Roche. Proposal of recommendations for a personalized precision medicine national strategy. 2017. https://www.institutoroche.es/static/pdfs/Propuesta_de_Recomendaciones_MPP_INGLES.pdf. Accessed 5 Sept 2018.
  61. 61.
    Merrill J. Multi-indication pricing: big hurdles and actionable options. Pharma Intelligence Informa. 2016; 78. https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-issue-pdfs/p160530.pdf?la = en. Accessed 15 Dec 2017.
  62. 62.
    Garattini L, Curto A, Freemantle N. Pharmaceutical price schemes in Europe: time for a “continental” one? Pharmacoeconomics. 2016;34:423–6.CrossRefGoogle Scholar
  63. 63.
    IMS Institute. Developments in cancer treatments, market dynamics, patient access and value. Global oncology trend report. 2015. https://www.keionline.org/sites/default/files/IIHI_Oncology_Trend_Report_2015.pdf. Accessed 5 Sept 2018.
  64. 64.
    Pearson SD, Dreitlein WB, Henshall C, Towse A. Indication-specific pricing of pharmaceuticals in the US healthcare system. J Comp Eff Res. 2017;6:397–404.CrossRefGoogle Scholar
  65. 65.
    Abedi S, IMS Consulting Group. Indication-specific pricing. The good, the bad, and the ugly. 2016. http://www.ehcca.com/presentations/PharmaMM/abedi_c.pdf. Accessed 5 Oct 2017.
  66. 66.
    Hebborn A. Value-based pricing across indications: a company perspective. 2014. https://www.ispor.org/meetings/montreal0614/presentations/IP14-AnsgarHebborn.pdf. Accessed 16 Nov 2017.
  67. 67.
    Belgian Health Care Knowledge Centre. How to improve the Belgian process for managed entry agreements? An analysis of the Belgian and international experience. KCE Report 288. 2017. https://kce.fgov.be/sites/default/files/atoms/files/T%C3%A9l%C3%A9charger%20le%20rapport%20en%20anglais%20(75%20p.).pdf. Accessed 5 Sept 2018.
  68. 68.
    National Health Service, Department of Health. The pharmaceutical price regulation scheme 2014. 2013. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/621983/2014_PPRS_Scheme.pdf/. Accessed 5 Sept 2018.
  69. 69.
  70. 70.
    NICE. Review of TA176; cetuximab for the first line treatment of metastatic colorectal cancer. 2009. https://www.nice.org.uk/guidance/ta176/documents/ta176-colorectal-cancer-first-line-cetuximab-appendix-b-proposal-paper-presented-to-the-institutes-guidance-executive2. Accessed 5 Sept 2018.
  71. 71.
    Xcenda AmerisourceBerge. Indication-specific pricing: what should manufacturers expect in key markets. 2017. https://www.xcenda.com/insights/htaq-winter-2017-indication-specific-pricing. Accessed 16 Nov 2017.
  72. 72.
    Roche facilita a las CCAA un sistema de gestión del precio por indicación. Diariofarma. 2017. https://www.diariofarma.com/2017/11/14/roche-facilita-las-ccaa-sistema-gestion-del-precio-indicacion. Accessed 16 Nov 2017.

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Independent Economics ConsultantMadridSpain
  2. 2.Weber Economía y SaludMadridSpain
  3. 3.Fundación Weber, MajadahondaMadridSpain
  4. 4.Universidad de Castilla-La Mancha, Campus de ToledoToledoSpain

Personalised recommendations